On 8 July 2022, the Decision Amending the Decision on Pricing of Medicinal Products for Human Use (Turkish language) was published on the Official Gazette numbered 31890. The Decision on Pricing of Medicinal Products for Human Use (Decision) is the legislation which set the rules on pricing of the human medicinal products.
The amendments to the Decision include:
- An increase in pharmacist profit rates to be applied when determining the retail sale price of the products.
- A new article, which increases the FX euro rate to be applied for calculating the pricing of human medicinal products by the Medicines and Medical Devices Agency (Agency). Before the amendment, the FX rate to be applied was updated by the Agency once every year in February. Pursuant to the Decision, the euro exchange rate is determined as 60% of the average euro value of the previous year.
- The existing calculated FX rate has been increased by 25% as of July 2022. Accordingly, the 1 euro value in Turkish Lira to be used in the pricing of medicinal products for human use was increased by 25% in July 2022 and the FX rate of TRY6.2925 determined on 14 February 2022 has been increased to TRY7.8656.
First published by Practical Law Life Sciences Monthly Newsletter in Jul 08, 2022.